SCHEMBL22835196

SCHEMBL22835196

CCOC(=O)c1cnc(N)nc1OC1CCCC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.54
KDM4E B2RXH2 4/20 0.53
CSNK1D P48730 2/20 0.49
LMNA P02545 1/20 0.46
ALDH1A1 P00352 4/20 0.43
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
RAB9A P51151 6/20 0.43
NPC1 O15118 5/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
MAPT P10636 2/20 0.43
TP53 P04637 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
NR2F2 P24468 1/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29652040 1.00 HSP90AA1 (0.54) HSP90AA1KDM4ECSNK1DLMNAALDH1A1
SCHEMBL28721952 0.86 OPRK1 (0.40) HSP90AA1KDM4EALDH1A1PDE4B
SCHEMBL1015157 0.85 CSNK1D (0.43) HSP90AA1KDM4ECSNK1DLMNAALDH1A1
SCHEMBL29598201 0.83 MAPK8 (0.40) HSP90AA1KDM4EALDH1A1
SCHEMBL22835026 0.83 MAPK8 (0.40) HSP90AA1KDM4EALDH1A1
SCHEMBL30830249 0.83 CSNK1D (0.53) HSP90AA1KDM4ECSNK1DLMNAALDH1A1
SCHEMBL26984563 0.83 CSNK1D (0.53) HSP90AA1KDM4ECSNK1DLMNAALDH1A1
SCHEMBL10995375 0.81 HSP90AA1 (0.65) HSP90AA1KDM4ECSNK1DLMNAALDH1A1
SCHEMBL31361711 0.81 KMT2A (0.58) KDM4ELMNAALDH1A1SMN1; SMN2MAPT
SCHEMBL14590443 0.80 HSP90AA1 (0.63) HSP90AA1KDM4ECSNK1DLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230087118-A1 IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE BIOGEN MA INC. 2023-03-23 US disclosed
EP-3990454-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE Biogen MA Inc. (US) 2022-05-04 EP disclosed
CN-114245796-A Imidazo [1,2-a ] pyridinyl derivatives and their use in the treatment of disease 比奥根MA公司 2022-03-25 CN disclosed
WO-2020263980-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE BIOGEN MA INC. (US) 2020-12-30 WO disclosed
WO-2020263980-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE BIOGEN MA INC. (US) 2020-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230087118-A1 IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE IRAK4, IRAK2, IRAK1 HSP90AA1 4691/4885KDM4E 114/4885CSNK1D 357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.